Literature DB >> 26773765

Risk factors of mortality after surgical correction of ventricular septal defect following myocardial infarction: Retrospective analysis and review of the literature.

Alexandre Cinq-Mars1, Pierre Voisine2, François Dagenais2, Éric Charbonneau2, Frédéric Jacques2, Dimitris Kalavrouziotis2, Jean Perron2, Siamak Mohammadi2, Michelle Dubois1, Florent Le Ven3, Paul Poirier3, Kim O'Connor3, Mathieu Bernier3, Sébastien Bergeron3, Mario Sénéchal4.   

Abstract

BACKGROUND: Rupture of the ventricular septum following acute myocardial infarction (AMI) is an uncommon but serious complication, usually leading to congestive heart failure and cardiogenic shock. Surgical repair is the only definitive treatment for this condition.
METHODS: We review our experience of surgical repair of post-infarction ventricular septal defects (VSDs), analyze the associated risk factors and outcomes, and do a complete review of the literature. A retrospective study was performed on 34 consecutive patients who had undergone surgical repair for VSDs following AMI from December 1991 to July 2014. Preoperative, clinical and echocardiographic variables were studied by uni-and multivariate analyses.
RESULTS: Mortality was analyzed for the entire group of patients. Mean age was 69 ± 7 years with 44% women. VSDs were anterior in 11 (32%) and posterior in 23 (68%) patients. A majority, 24 (71%) patients were in cardiogenic shock. Median interval from myocardial infarction to VSDs repair was 7 days. The 30 days operative mortality was 65%. Mortality within the posterior VSDs group was 74% and the anterior VSDs group was 46% (P=0.14). Concomitant coronary artery bypass graft (CABG) did not influence early or late survival. Multivariate analysis identified older age (HR=1.11, P=0.0001) and shorter time between AMI and surgery (HR=0.90, P=0.015) as independent predictors of 30-day and long-term mortality.
CONCLUSION: In conclusion, surgical repair of post-AMI VSDs carries a high operative mortality. An algorithm of treatment for the management of these patients is suggested.
Copyright © 2015. Published by Elsevier Ireland Ltd.

Entities:  

Keywords:  Myocardial infarction; Outcomes; Risk factors; Ventricular septal defect

Mesh:

Year:  2015        PMID: 26773765     DOI: 10.1016/j.ijcard.2015.12.011

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  11 in total

Review 1.  Triple patch technique to repair ventricular septal rupture.

Authors:  Yuki Okamoto; Kazuo Yamamoto; Shinpei Yoshii
Journal:  Ann Cardiothorac Surg       Date:  2022-05

2.  Effects of concomitant coronary artery bypass grafting on early and late mortality in the treatment of post-infarction mechanical complications: a systematic review and meta-analysis.

Authors:  Daniele Ronco; Claudio Corazzari; Matteo Matteucci; Giulio Massimi; Michele Di Mauro; Justine M Ravaux; Cesare Beghi; Roberto Lorusso
Journal:  Ann Cardiothorac Surg       Date:  2022-05

3.  Surgical management for mechanical complications of acute myocardial infarction: a systematic review of long-term outcomes.

Authors:  Sarah Yousef; Ibrahim Sultan; Helena M VonVille; Kevin Kahru; George J Arnaoutakis
Journal:  Ann Cardiothorac Surg       Date:  2022-05

4.  Post-infarction ventricular septal defect with cardiogenic shock: peripheral veno-arterial extracorporeal membrane oxygenator as a bridge to surgery.

Authors:  Vishal Khullar; Kukbin Choi; Kevin Greason
Journal:  Indian J Thorac Cardiovasc Surg       Date:  2022-01-05

5.  Transcatheter closure of ventricular septal rupture with prolonged support of intra-aortic balloon pump after primary PCI: a case report.

Authors:  Chuan Yang; Yong Sun; Deling Zou; Zhaoqing Sun; Xinzhong Zhang; Guangsheng Su; Jing Qi; Wenyue Pang
Journal:  BMC Cardiovasc Disord       Date:  2021-12-18       Impact factor: 2.298

6.  Surgical Treatment of Postinfarction Ventricular Septal Rupture.

Authors:  Daniele Ronco; Matteo Matteucci; Mariusz Kowalewski; Michele De Bonis; Francesco Formica; Federica Jiritano; Dario Fina; Thierry Folliguet; Nikolaos Bonaros; Claudio Francesco Russo; Sandro Sponga; Igor Vendramin; Carlo De Vincentiis; Marco Ranucci; Piotr Suwalski; Giosuè Falcetta; Theodor Fischlein; Giovanni Troise; Emmanuel Villa; Guglielmo Actis Dato; Massimiliano Carrozzini; Giuseppe Filiberto Serraino; Shabir Hussain Shah; Roberto Scrofani; Antonio Fiore; Jurij Matija Kalisnik; Stefano D'Alessandro; Vittoria Lodo; Adam R Kowalówka; Marek A Deja; Salman Almobayedh; Giulio Massimi; Matthias Thielmann; Bart Meyns; Fareed A Khouqeer; Nawwar Al-Attar; Matteo Pozzi; Jean-François Obadia; Udo Boeken; Nikolaos Kalampokas; Carlo Fino; Caterina Simon; Shiho Naito; Cesare Beghi; Roberto Lorusso
Journal:  JAMA Netw Open       Date:  2021-10-01

7.  The evaluation of levosimendan in patients with acute myocardial infarction related ventricular septal rupture undergoing cardiac surgery: a prospective observational cohort study with propensity score analysis.

Authors:  Ze-Shi Li; Kuo Wang; Tuo Pan; Yan-Hua Sun; Chang Liu; Yong-Qing Cheng; He Zhang; Hai-Tao Zhang; Dong-Jin Wang; Zu-Jun Chen
Journal:  BMC Anesthesiol       Date:  2022-05-03       Impact factor: 2.376

8.  Post-Myocardial Infarction Ventricular Septal Defect Successfully Treated with Impella as Bridge to Cardiac Transplantation.

Authors:  Lauren Giudicatti; Benjamin Silbert; Xiao-Fang Xu; Anthony Putrino; Felicity Lee; Amit Shah; Robert Larbalestier; Karim Slimani; Andrew Laycock; Kaitlyn Lam
Journal:  Case Rep Cardiol       Date:  2022-07-31

9.  In-hospital outcome of patients with post-MI VSD: a single-center study.

Authors:  Mohsen Abbasnejad; Mehdi Tahmasebi Vand; Zhila Khamnian; Ahmad Separham
Journal:  Kardiochir Torakochirurgia Pol       Date:  2018-12-31

10.  Cardiac rupture complicating acute myocardial infarction: the clinical features from an observational study and animal experiment.

Authors:  Qun Lu; Ping Liu; Jian-Hua Huo; Yan-Ni Wang; Ai-Qun Ma; Zu-Yi Yuan; Xiao-Jun Du; Ling Bai
Journal:  BMC Cardiovasc Disord       Date:  2020-09-10       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.